FREMONT, Calif., May 17, 2024--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that the Compensation Committee of its Board of Directors granted, on May 15, 2024, a non-qualified stock option to purchase an aggregate of 85,000 shares of its common stock to Personalis’ new Vice President, Customer Experience under Personalis’ 2020 Inducement Plan.
We can readily understand why investors are attracted to unprofitable companies. For example, although...
Personalis ( NASDAQ:PSNL ) First Quarter 2024 Results Key Financial Results Revenue: US$19.5m (up 3.5% from 1Q 2023...